Targeting TROP-2 in Prostate Cancer Using Site-Specifically Radiolabeled IMMU-132 with ⁸⁹Zr via 3,4,3-LI(1,2-HOPO)
Syed Qaiser Shah, Ralph Santos-Oliveira, DeryaIlem Ozdemir, Saba Shirin · Nuklearmedizin - NuclearMedicine · 2025 · Heft 06 · S. 332-340
Bibliografische Angaben
Zusammenfassung
Abstract Aim To develop a site-specifically radiolabeled version of IMMU-132 (sacituzumab govitecan) using zirconium-89 (⁸⁹Zr) with the chelator 3,4,3-LI(1,2-HOPO) and evaluate its stability, specificity, and quantitative targeting ability in TROP-2–positive prostate cancer models. Methods IMMU-132 was conjugated to 3,4,3-LI(1,2-HOPO)-maleimide and its integrity was confirmed by SDS-PAGE, SE-HPLC and mass spectrometry. Radiolabeling with ⁸⁹Zr was performed, and radiochemical yield and purity were measured. In vitro stability was assessed in human serum at 37 °C for 120 h. Binding affinity and specificity were ev…
